Aprogen

Aprogen, founded in 2000 and headquartered in Seongnam, South Korea, is a biopharmaceutical company focused on biosimilar development and manufacturing. The company developed South Korea's first approved antibody biosimilar in 2006 and has since expanded its pipeline to include biosimilars for infliximab, trastuzumab, adalimumab, rituximab, and cetuximab, as well as novel bispecific antibody therapeutics. Aprogen is listed on the KOSPI exchange.